Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2019-03-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于2019年与重要股东日常关联预估的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the estimated daily related-party transactions with important shareholders for the year 2019. It includes details about the nature of the transactions, estimated and actual amounts for 2018 and 2019, related parties, pricing policies, and the impact on the company and shareholders. The document is an announcement about related-party transactions and their estimates, not a full financial report or audit. It does not contain comprehensive financial statements or detailed management analysis. It is also not a voting result, board change, or legal proceeding. The document fits best into the category of Regulatory Filings (RNS) as it is a regulatory announcement about related-party transactions required by stock exchange rules but does not constitute a full report or financial statement.
2019-03-22 Chinese
独立董事关于昆药集团九届七次董事会相关事项的独立意见
Audit Report / Information Classification · 95% confidence The document is an independent directors' opinion on various company matters related to the 2018 fiscal year, including the 2018 profit distribution plan, the 2018 annual report, daily related party transactions, management performance responsibility, and credit guarantees. It references the 2018 annual report and provides opinions on its preparation and compliance but does not contain the full annual report itself. The document is relatively short (2133 characters) and serves as an independent opinion or certification related to the annual report and other governance matters. It does not contain full financial statements or detailed financial data typical of an Annual Report (10-K). Instead, it is an audit-related opinion or independent directors' statement on governance and financial matters. Therefore, the best classification is Audit Report / Information (AR). FY 2018
2019-03-22 Chinese
关于为控股公司提供担保的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement by Kunming Pharmaceutical Group Co., Ltd. regarding guarantees provided by the company for its subsidiaries. It details the guarantee amounts, the subsidiaries involved, their financial status as of December 31, 2018, and the board's opinion on the guarantees. The document is a regulatory announcement about financial guarantees and does not contain financial statements or detailed financial performance data. It is not an annual or interim report, nor is it a call transcript or management report. It is also not a report publication announcement since it contains substantive information. The content fits best under a general regulatory announcement category related to compliance and disclosures about guarantees. Therefore, the appropriate classification is Regulatory Filings (RNS).
2019-03-22 Chinese
中审众环关于昆药集团2018年财务审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" which translates to "Audit Report". It contains detailed audit opinions, basis for audit opinions, key audit matters, responsibilities of management and auditors, and extensive notes on accounting policies and financial statement preparation. The content includes audit procedures, financial statement notes, and accounting standards compliance, which are typical components of a standalone audit report. The document is about the audit of the 2018 financial statements of Kunming Pharmaceutical Group Co., Ltd. It is not an annual report itself but the auditor's report on the financial statements. The length is substantial (15,000 characters), indicating it is the full audit report rather than a brief announcement. Therefore, the document fits the category of Audit Report / Information (AR). FY 2018
2019-03-22 Chinese
募集资金存放与实际使用情况的专项鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a verification report on the storage and actual use of raised funds for the year ended December 31, 2018. It is an attestation by certified public accountants regarding a special report prepared by the company's board in compliance with regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange. The document contains an auditor's opinion on the special report about fundraising usage, indicating it is a standalone audit or assurance report related to fundraising activities, not a full annual report or interim financial report. The document length is short (937 characters), but it contains substantive auditor opinion and verification procedures, consistent with an Audit Report / Information filing rather than a mere announcement or certification. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2018
2019-03-22 Chinese
中审众环关于昆药集团2018年内控审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It references auditing standards and responsibilities related to internal control over financial reporting for the fiscal year ending December 31, 2018. The document contains an auditor's opinion on the effectiveness of internal controls, mentions specific auditing guidelines, and includes signatures of certified public accountants. The length is about 1063 characters, which is relatively short but contains substantive audit content rather than just an announcement. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles. It is not an Annual Report (10-K) or a Regulatory Filing (RNS) because it contains detailed audit opinion content rather than a brief announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2018
2019-03-22 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.